Inclusion Criteria:

          -  Have evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1
             (RECIST 1.1).

          -  In the judgment of the investigator, be an appropriate candidate for experimental
             therapy and:

               -  For Cohort A only: Have exhausted all anticancer treatments with proven clinical
                  benefit OR

               -  For Cohorts B and C only: Must have one of the three conditions below:

                    -  Have exhausted all anti-cancer treatments with proven clinical benefit, OR

                    -  Have hepatocellular carcinoma or gastric cancer who have received prior
                       treatment, and where IV ramucirumab monotherapy is clinically acceptable
                       treatment after progression OR

                    -  Have a diagnosis for which IV ramucirumab in combination with additional
                       anticancer therapy is clinically acceptable treatment

                    -  Additionally, it must be clinically acceptable to delay initiation of the
                       combination partner for 3 weeks from the initiation of ramucirumab dosing.

          -  Eastern Cooperative Oncology Group performance status score of 0 or 1.

          -  Have discontinued all previous treatments for cancer with adequate wash-out period and
             recovered from the acute effects of therapy.

          -  Have adequate hematologic, hepatic, and renal functions and electrolytes.

          -  Males and females of child-bearing potential must agree to use highly effective
             contraceptive methods during study treatment and for at least 84 days/12 weeks
             following the last dose of study drug.

        Exclusion Criteria:

          -  Have uncontrolled hypertension defined as systolic blood pressure (BP) >150 mmHg or
             diastolic BP >90 mmHg despite standard medical management.

          -  Have significant bleeding disorders or experienced Grade 3/4 gastrointestinal (GI)
             bleeding within 3 months prior to enrollment.

          -  Have hepatic impairment (such as severe liver cirrhosis Child-Pugh B [or worse],
             cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites
             requiring ongoing treatment with diuretics and/or paracentesis, or history of
             hepatorenal syndrome).

          -  Have experienced any arterial thromboembolic events (ATEs), including but not limited
             to myocardial infarction, transient ischemic attack, cerebrovascular accident, or
             unstable angina, ≤6 months prior to randomization.

          -  The participant has clinically relevant congestive heart failure (CHF; New York Heart
             Association [NYHA] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.

          -  Have symptomatic central nervous system (CNS) metastases. Screening is not required.

          -  Have history of GI perforation and/or fistula within 6 months prior to enrollment.

          -  Have an active uncontrolled systemic bacterial, viral, or fungal infection or serious
             ongoing uncontrolled intercurrent illness.

          -  Have a serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to
             enrollment.

          -  Have received IV ramucirumab in the past.